Published in
Taylor and Francis Group, OncoImmunology, 5(4), p. e1005501
DOI: 10.1080/2162402x.2015.1005501
Links
- ORCID
- Taylor and Francis Group
- [researchrepository.murdoch.edu.au]
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [researchrepository.murdoch.edu.au] | PDF
Tools
Restoration of defective cross-presentation in tumors by gemcitabine
Journal article published in 2015 by
Alison M. McDonnell,
W. Joost Lesterhuis 
,
Andrea Khong,
Anna K. Nowak,
Richard A. Lake,
Andrew J. Currie,
Bruce Ws S. Robinson
,
Andrea Khong,
Anna K. Nowak,
Richard A. Lake,
Andrew J. Currie,
Bruce Ws S. Robinson
This paper is available in a repository.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Tumor antigen cross-presentation by dendritic cells (DCs) to specific CD8(+) T cells is central to antitumor immunity. Although highly efficient in draining lymph nodes, it is defective within the tumor site itself. Importantly, an immunogenic chemotherapy, gemcitabine, reverses this defect, allowing the potential re-stimulation of cytotoxic T lymphocytes within tumor sites.